FDA
-
-
-
-
-
-
-
Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
-
-
-
-
-
-
-
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
-
-
-
-
-
-
-
Novan (NOVN) Prioritizes Late-Stage Assets; Outlines Key Milestones
-
-
-
-
-
-
-
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
-
-
-
-
-
-
-
Acerus and Aytu Bioscience to Co-promote Natesto® in the United States
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vanda Pharmaceuticals, AVEO Pharmaceuticals, Stamps.com, and Syneos and Encourages Investors to Contact
-
-
-
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

